Amgen Announces $650 Million Expansion of U.S. Manufacturing Network, Creating Jobs

What's Happening?

Amgen has announced a $650 million investment to expand its U.S. manufacturing network, specifically at its biologics manufacturing facility in Juncos, Puerto Rico. This expansion is expected to create approximately 750 jobs, including construction and highly skilled manufacturing roles. The investment will support increased drug production and integrate advanced technologies throughout the operations process. Amgen's CEO, Robert A. Bradway, emphasized the company's commitment to U.S. biomanufacturing and strengthening the resilience of its global supply chain. The expansion reflects Amgen's long-standing commitment to U.S. innovation, with over $40 billion invested in manufacturing and research and development since the Tax Cuts and Jobs Act of 2017.

Why It's Important?

This expansion is significant as it reinforces America's leadership in biotechnology and strengthens the U.S. supply chain. By creating high-quality jobs and integrating cutting-edge technology, Amgen is contributing to the U.S. economy and the biopharmaceutical sector. The investment also highlights the impact of pro-growth tax policies, which have facilitated domestic investments in science and manufacturing. The expansion in Puerto Rico, a key hub for biopharmaceuticals, underscores the island's role in the U.S. biopharmaceutical industry, supported by a skilled workforce and world-class infrastructure.

What's Next?

Amgen's expansion is part of a broader effort to advance U.S. innovation and manufacturing. The company has also committed $900 million to expand its New Albany, Ohio, facility and $1 billion to build a second factory in Holly Springs, North Carolina. These investments are expected to further bolster Amgen's manufacturing capabilities and support its growth in the biopharmaceutical sector.